Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. (AUPH): 6 pipeline candidates · 1 upcoming catalyst · ~18 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
17.6 months
D/E 0.28 · 5% dilution
Lead: Phase 3
6 candidates
1 upcoming, next in ~4190d
11 buys · 0 sells (180d)
A transparent, data-derived signal for Aurinia Pharmaceuticals Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.1B
Cash
$41.0M
Quarterly Burn
$29.5M
Runway
17.6 mo
Revenue
$77.7M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| aritinercept | Phase 1/Phase 2 |
| AUR200 | Phase 1 |
| belimumab | Phase 4 |
| LUPKYNIS | Phase 4 |
| mycophenolic acid analog | Phase 4 |
| voclosporin | Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
258
Total value held
$1.04B
| Holder | Shares | Value |
|---|---|---|
| tang capital management llc | 12,229,500 | $181.2M |
| blackrock, inc. | 7,845,521 | $116.3M |
| two sigma investments, lp | 3,428,705 | $50.8M |
| arrowstreet capital, limited partnership | 3,284,368 | $48.7M |
| state street corp | 2,527,099 | $37.5M |
| morgan stanley | 2,232,548 | $33.1M |
| marshall wace, llp | 1,874,597 | $27.8M |
| renaissance technologies llc | 1,663,835 | $24.7M |
| d. e. shaw & co., inc. | 1,572,983 | $23.3M |
| geode capital management, llc | 1,536,009 | $22.8M |
Showing top 10 of 258 institutional holders of Aurinia Pharmaceuticals Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Aurinia Pharmaceuticals Inc.'s pipeline?
Aurinia Pharmaceuticals Inc. (AUPH) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Aurinia Pharmaceuticals Inc.'s lead drug candidate?
Aurinia Pharmaceuticals Inc.'s most advanced tracked candidate is aritinercept (Phase 1/Phase 2) for Myasthenia Gravis, Generalized.
What is Aurinia Pharmaceuticals Inc.'s next catalyst?
Aurinia Pharmaceuticals Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: LUPKYNIS" — expected December 7, 2037.
What is Aurinia Pharmaceuticals Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Aurinia Pharmaceuticals Inc. has approximately 17.6 months of cash runway.
What is Aurinia Pharmaceuticals Inc.'s market capitalization?
Aurinia Pharmaceuticals Inc.'s market capitalization is approximately $2.1B.
Get the full picture on Aurinia Pharmaceuticals Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.